Evidence map›Paper›PMID 41882397›Full record

ReviewProgress in molecular and subcellular biology2026

Biotechnological Applications of Archaea.

Nalan Tavşanlı, Ahmet Arıhan Erözden, Muzaffer Arıkan, Mahmut Çalışkan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Progress in molecular and subcellular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nalan TavşanlıProgram of Biotechnology, Biology Department, Institute of Graduate Studies in Sciences, Istanbul University, Vezneciler, Istanbul, Türkiye.
Ahmet Arıhan ErözdenProgram of Biotechnology, Biology Department, Institute of Graduate Studies in Sciences, Istanbul University, Vezneciler, Istanbul, Türkiye.
Muzaffer ArıkanDivision of Biotechnology, Biology Department, Faculty of Science, Istanbul University, Vezneciler, Istanbul, Türkiye.
Mahmut ÇalışkanDivision of Biotechnology, Biology Department, Faculty of Science, Istanbul University, Vezneciler, Istanbul, Türkiye. mahmut.caliskan@istanbul.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Archaea are the "silent and unseen majority of life" with an extraordinary capacity to live in some of the most unfavorable habitats in nature, and continue to exist in regions with extreme features that are inhospitable to most other living organisms. They are prokaryotic and frequently found in environments with high pH, salinity, and temperatures. Asgard, Euryarchaeota, TACK, and DPANN are the four main superphyla that make up the Archaea, one of the three domains of life on Earth. Extremophiles, the first Archaea found, are classified into four major physiological types. These are halophiles, thermophiles, alkaliphiles, and acidophiles. The Archaea domain is the subject of extensive research, particularly for potential biotechnological applications. Archaea play a crucial role in environmental sustainability and human health, particularly through their enzymes, metabolites, and biochemical processes. These are some core characteristics of Archaea enabling biotechnological usage. This chapter aims to provide an overview of the various roles that Archaea have in biotechnological usage, both current and potential. Their classification is based on the industry to which the application is targeted, which includes industrial enzyme and catalysis, energy production, and medical and pharmaceutical applications.

Indexed as

ArchaeaBiotechnologyApplicationsArchaeaBiotechnologyExtremophilesMethanogens

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.